Literature DB >> 20649760

Double filtration plasmapheresis in antibody-incompatible kidney transplantation.

Rob Higgins1, David Lowe, Mark Hathaway, For T Lam, Habib Kashi, Lam Chin Tan, Chris Imray, Simon Fletcher, Klaus Chen, Nithya Krishnan, Rizwan Hamer, Daniel Zehnder, David Briggs.   

Abstract

Double filtration plasmapheresis (DFPP) was used in preference to plasma exchange in our program of antibody-incompatible transplantation, to treat higher volumes of plasma. Forty-two patients had 259 sessions of DFPP, 201 pre-transplant and 58 post-transplant. At the first treatment session, the mean plasma volume treated was 3.81 L (range 3-6 L), 55.5 mL/kg (range 36.2-83.6 mL/kg). Serum IgG fell by mean 59.4% (SD 10.2%), and IgM by 69.3% (SD 16.1%). Nine patients did not require increases in plasma volumes treated, and six did not tolerate higher plasma volumes. In the remaining patients, the mean maximum plasma volume treated pre-transplant was 6.67 L (range 4-15 L), 96.1 mL/kg (range 60.2-208.9 mL/kg). The complement dependent cytotoxic crossmatch was positive in 14 cases pre-treatment, and remained positive in six (42.8%) cases. The flow cytometric crossmatch was positive in 29 cases pre-treatment, and in 21 (72.4%) after DFPP. Post-transplant, DFPP was ineffective at reducing donor specific antibody levels during periods of rapid donor specific antibody synthesis. Post-transplant, the one year graft survival rate was 94%, although there was a high rate of early rejection. In summary, DFPP enabled the treatment of plasma volumes that were almost double those that would have been feasible with plasma exchange. Despite this, most patients were transplanted with a positive crossmatch, and DFPP post-transplant was unable to control rising antibody levels.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20649760     DOI: 10.1111/j.1744-9987.2010.00821.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  10 in total

Review 1.  Role of therapeutic plasmapheresis in ANCA-associated vasculitis.

Authors:  Giles Walters
Journal:  Pediatr Nephrol       Date:  2015-05-19       Impact factor: 3.714

Review 2.  Antibody-incompatible kidney transplantation in 2015 and beyond.

Authors:  Rob M Higgins; Sunil Daga; Dan A Mitchell
Journal:  Nephrol Dial Transplant       Date:  2014-12-13       Impact factor: 5.992

Review 3.  Rational clinical trial design for antibody mediated renal allograft injury.

Authors:  Shaifali Sandal; Martin S Zand
Journal:  Front Biosci (Landmark Ed)       Date:  2015-01-01

4.  ABO Incompatible Kidney Transplantation-Current Status and Uncertainties.

Authors:  Milljae Shin; Sung-Joo Kim
Journal:  J Transplant       Date:  2011-12-10

5.  Current progress in ABO-incompatible kidney transplantation.

Authors:  Tai Yeon Koo; Jaeseok Yang
Journal:  Kidney Res Clin Pract       Date:  2015-08-20

6.  Clinical analysis of single filtration plasmapheresis using continuous renal replacement therapy machines in kidney transplantation.

Authors:  Eunsoo Lim; Yujeong Kim; Jong Cheol Jeong; Inwhee Park; Heungsoo Kim; Su Hyung Lee; Chang-Kwon Oh; Gyu-Tae Shin
Journal:  Kidney Res Clin Pract       Date:  2017-06-30

7.  Reduced functional measure of cardiovascular reserve predicts admission to critical care unit following kidney transplantation.

Authors:  Stephen M S Ting; Hasan Iqbal; Thomas Hamborg; Chris H E Imray; Susan Hewins; Prithwish Banerjee; Rosemary Bland; Robert Higgins; Daniel Zehnder
Journal:  PLoS One       Date:  2013-05-27       Impact factor: 3.240

8.  Innate functions of immunoglobulin M lessen liver gene transfer with helper-dependent adenovirus.

Authors:  Carmen Unzu; Ignacio Melero; Aizea Morales-Kastresana; Ana Sampedro; Irantzu Serrano-Mendioroz; Arantza Azpilikueta; María Carmen Ochoa; Juan Dubrot; Eduardo Martínez-Ansó; Antonio Fontanellas
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

9.  Apheresis Efficacy and Tolerance in the Setting of HLA-Incompatible Kidney Transplantation.

Authors:  Johan Noble; Antoine Metzger; Hamza Naciri Bennani; Melanie Daligault; Dominique Masson; Florian Terrec; Farida Imerzoukene; Beatrice Bardy; Gaelle Fiard; Raphael Marlu; Eloi Chevallier; Benedicte Janbon; Paolo Malvezzi; Lionel Rostaing; Thomas Jouve
Journal:  J Clin Med       Date:  2021-03-23       Impact factor: 4.241

Review 10.  Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization.

Authors:  Ashley Y Choi; Miriam Manook; Danae Olaso; Brian Ezekian; Jaeberm Park; Kyle Freischlag; Annette Jackson; Stuart Knechtle; Jean Kwun
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.